Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof
Modified forms of hemagglutinin (HA) protein including those with modified immunodominant regions and with modified maturation cleavage sites, and virus and virus-like particles containing them are disclosed.
1. A modified influenza virus wherein said virus comprises an influenza HA protein wherein the maturation cleavage site (MCS) thereof has been modified so as not to be cleavable by any animal proteases but to remain cleavable by a non-animal protease.
2. The modified influenza virus of claim 1 wherein the MCS has been modified to be cleavable by a tobacco etch viral (TEV) protease.
3. The modified influenza virus of claim 1 wherein the MCS has been cleaved by an appropriate protease.
4. The modified influenza virus of claim 2 wherein the MCS has been cleaved by a TEV protease.
5. The modified influenza virus of claim 3 wherein an immunogenic epitope heterologous to the globular region of the HA protein has been inserted into or has replaced at least one immunodominant region in the globular head domain of said HA protein.
6. The modified influenza virus of claim 5 wherein the heterologous immunogenic epitope is of a tumor associated antigen or an epitope of a virus other than influenza or an alternate influenza epitope.
7. The modified influenza virus of claim 6 wherein the heterologous immunogenic epitope is a conserved region of an HA stem region.
8. The modified influenza virus of claim 5 wherein more than one immunodominant region of said HA protein has been modified to contain a heterologous epitope.
9. The modified influenza virus of claim 8 wherein at least some of the heterologous epitopes contained in each of said more than one immunodominant regions are different from each other.
10. A flu vaccine comprising the modified influenza virus of claim 1 .
11. A flu vaccine comprising the modified influenza virus of claim 3 .
12. A flu vaccine comprising the modified influenza virus of claim 7 .
13. A method to generate antibodies against flu which method comprises administering to a subject the flu vaccine of any of claims 10 - 12 .
14. A method for prophylactic treatment of a subject against flu which method comprises administering the vaccine of any of claims 10 - 12 to said subject.
15. A method to generate antibodies against a desired antigen which method comprises administering to a subject the modified influenza virus of claim 5 .
16. A nucleic acid encoding at least an effective portion of an influenza HA protein wherein the nucleotide sequence encoding the MCS thereof is modified to encode an MCS that is not cleavable by any animal proteases but is cleavable by a non-animal protease and has not been cleaved.
17. The nucleic acid of claim 16 wherein said MCS is modified to encode an MCS that is cleavable by a TEV protease.
18. The nucleic acid of claim 17 wherein an immunogenic epitope heterologous to the globular region of the HA protein has been inserted into or has replaced at least one immunodominant region in the globular head domain of said HA protein.
19. Recombinant host cells that produce a modified virus or virus-like particle that comprise the at least an effective portion of HA protein encoded by the nucleic acid of claim 16 .
20. A method to prepare a virus or virus-like particle comprising a modified HA protein which method comprises culturing the recombinant host cells of claim 19 under conditions wherein said nucleic acid is expressed and recovering the virus or virus-like particle comprising said at least an effective portion of said HA protein.